Market Access/ News/ News NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic Phil Taylor Bristol-Myers Squib, Cancer Drugs Fund, Inrebic, JAK inhibitor, myelofibrosis, NHS, NICE 0 Comment After turning down routine NHS funding of Bristol-Myers Squibb’s Inrebic for bone marrow disorder myelofibrosis earlier this year, Share X NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic https://pharmaphorum.com/news/nice-changes-tack-on-nhs-use-of-bms-myelofibrosis-drug-inrebic/